Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: michael liu who wrote (13951)	11/20/1998 9:11:00 AM
From: The Foxman	Respond to of 119973

CRGN News! 11/20 7:02A (DJ) +Curagen, Glaxo Wellcome In Drug Discovery Collaboration Story 1457 Curagen - Collaboration -2: To Identify Drug Candidates NEW HAVEN, Conn. (Dow Jones)--CuraGen Corp. (CRGN) and Glaxo Wellcome Inc. (GLX) formed a five-year drug discovery collaboration. In a press release Friday, CuraGen said Glaxo Wellcome will use its integrated genomics processes to study and select Glaxo Wellcome compounds for clinical development. CuraGen will evaluate compounds across Glaxo Wellcome's therapeutic programs, identifying gene responses associated with compound efficacy and toxicity. The collaboration allows Glaxo Wellcome to select drug candidates with the highest likelihood of success in clinical trials.